{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T17:48:19Z","timestamp":1785865699720,"version":"3.56.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.dsx.2022.102697","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T11:42:26Z","timestamp":1671795746000},"page":"102697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Efficacy and safety of novel thiazolidinedione lobeglitazone for managing type-2 diabetes a meta-analysis"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4915-8805","authenticated-orcid":false,"given":"Deep","family":"Dutta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saptarshi","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyankar K.","family":"Datta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritin","family":"Mohindra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dsx.2022.102697_bib1","doi-asserted-by":"crossref","first-page":"12953","DOI":"10.1074\/jbc.270.22.12953","article-title":"An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)","volume":"270","author":"Lehmann","year":"1995","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.dsx.2022.102697_bib2","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1572-0241.2000.01707.x","article-title":"Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration","volume":"95","author":"Kohlroser","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dsx.2022.102697_bib3","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.dsx.2022.102697_bib4","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1185\/030079906X112598","article-title":"Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study","volume":"22","author":"Hanefeld","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.dsx.2022.102697_bib5","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.dsx.2022.102697_bib6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12933-021-01294-7","article-title":"Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug","volume":"20","author":"Nesti","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.dsx.2022.102697_bib7","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4093\/dmj.2020.0272","article-title":"Lobeglitazone: a novel thiazolidinedione for the management of type 2 diabetes mellitus","volume":"45","author":"Bae","year":"2021","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.dsx.2022.102697_bib8","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3803\/EnM.2017.32.3.389","article-title":"Effects of lobeglitazone, a new thiazolidinedione, on osteoblastogenesis and bone mineral density in mice","volume":"32","author":"Kim","year":"2017","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.dsx.2022.102697_bib9","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/jat.2918","article-title":"CKD-501, a novel selective PPAR\u03b3 agonist, shows no carcinogenic potential in ICR mice following oral administration for 104 weeks","volume":"34","author":"Moon","year":"2014","journal-title":"J\u00a0Appl Toxicol"},{"key":"10.1016\/j.dsx.2022.102697_bib10","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/dom.12435","article-title":"Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension","volume":"17","author":"Jin","year":"2015","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.dsx.2022.102697_bib11","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1111\/dom.14085","article-title":"Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks","volume":"22","author":"Kim","year":"2020","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.dsx.2022.102697_bib12","article-title":"Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo controlled trial","volume":"9","author":"Kim","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.dsx.2022.102697_bib13","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1111\/dom.14766","article-title":"A\u00a0double-blind, Randomized controlled trial on glucose-lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase-4 inhibitor therapy: REFIND study","volume":"24","author":"Ryang","year":"2022","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.dsx.2022.102697_bib14","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.dsx.2022.102697_bib15","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and metaanalyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.dsx.2022.102697_bib16","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3803\/EnM.2020.818","article-title":"Efficacy and safety of the novel dipeptidyl peptidase-4 inhibitor gemigliptin in the management of type 2 diabetes: a meta-analysis","volume":"36","author":"Dutta","year":"2021","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.dsx.2022.102697_bib17","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ (Clinical research ed)"},{"key":"10.1016\/j.dsx.2022.102697_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta4100","article-title":"Publication and related biases","volume":"4","author":"Song","year":"2000","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.dsx.2022.102697_bib19","doi-asserted-by":"crossref","first-page":"377","DOI":"10.4093\/dmj.2017.41.5.377","article-title":"Effects of lobeglitazone, a novel thiazolidinedione, on bone mineral density in patients with type 2 diabetes mellitus over 52 weeks","volume":"41","author":"Lim","year":"2017","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.dsx.2022.102697_bib20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s13300-020-00948-1","article-title":"Comparative efficacy of lobeglitazone versus pioglitazone on albuminuria in patients with type 2 diabetes mellitus","volume":"12","author":"Kim","year":"2021","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.dsx.2022.102697_bib21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3346\/jkms.2017.32.1.60","article-title":"Lobeglitazone, a novel thiazolidinedione, improves non-alcoholic fatty liver disease in type 2 diabetes: its efficacy and predictive factors related to responsiveness","volume":"32","author":"Lee","year":"2017","journal-title":"J\u00a0Kor Med Sci"},{"key":"10.1016\/j.dsx.2022.102697_bib22","doi-asserted-by":"crossref","DOI":"10.4093\/dmj.2021.0264","article-title":"A\u00a0real-world study of long-term safety and efficacy of lobeglitazone in Korean patients with type 2 diabetes mellitus","author":"Kim","year":"2022","journal-title":"Diabetes Metab J"},{"issue":"1","key":"10.1016\/j.dsx.2022.102697_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2019-000807","article-title":"Therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and lobeglitazone in drug-na\u00efve patients with type 2 diabetes: initial triple study","volume":"8","author":"Lim","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.dsx.2022.102697_bib24","doi-asserted-by":"crossref","first-page":"dgz252","DOI":"10.1210\/clinem\/dgz252","article-title":"Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis","volume":"105","author":"Zhou","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.dsx.2022.102697_bib25","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2174\/22123911MTA5pMzA20","article-title":"Efficacy and cardiovascular safety of DPP-4 inhibitors","volume":"16","author":"Subrahmanyan","year":"2021","journal-title":"Curr Drug Saf"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402122003149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402122003149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:21:33Z","timestamp":1761729693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402122003149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1871402122003149"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2022.102697","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of novel thiazolidinedione lobeglitazone for managing type-2 diabetes a meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2022.102697","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Research Trust of DiabetesIndia (DiabetesIndia) and National Diabetes Obesity and Cholesterol Foundation (N-DOC). Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102697"}}